Q1 2025 Earnings Call Transcript May 8, 2025 Royalty Pharma plc beats earnings expectations. Reported EPS is $1.06, ...

Q1 2025 Earnings Call Transcript May 8, 2025 Crinetics Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...

The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...

In April 2025, our partner Jazz announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of ...

In addition to the presentations, Viral Kansara, PhD, Vice President, Preclinical Development moderated an ARVO session entitled "Retina/RPE: New drugs, mechanisms of action, and toxicity” and Dr.

Q1 2025 Earnings Conference Call May 8, 2025 7:30 AM ETCompany ParticipantsFabrice Chouraqui – CEOStephen Toor – ...

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's first-quarter ...

Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA c ...

Operator: Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement Q1 2025 Conference Call. I am George, the Chorus ...

The U.S. FDA has approved SELARSDI (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...

At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals First Quarter Earnings Conference Call. All participants will be in a listen-only mode. After today’s presentation there ...